Summary
The effect of omeprazole treatment on theophylline pharmacokinetics was studied in eight, non-smoking healthy male volunteers during repeated administration of a slow release formulation of theophylline. In a randomized double-blind cross-over study, the subjects received theophylline 5 mg·kg−1 per day with omeprazole 20 mg per day or identical placebo during two periods, each of 7 days, separated by a washout period of 7 days.
The oral clearance of theophylline remained unchanged whether it was administered alone or with omeprazole (54.2 ml·min−1). The average urinary excretion of theophylline and its metabolites, 1,3 dimethyluric acid (1,3-DMU), 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) amounted to 9%, 32%, 12% and 22% of the administered dose, respectively, and no significant change occured during concomitant treatment with omeprazole.
Thus, the formation and clearance of the metabolites was not altered by omeprazole. Consequently, omeprazole in the recommended dose of 20 mg daily can safely be administered to patients on theophylline therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Andersson T, Andre NK, Cederberg C, Edvardsson G, Heggelund A, Lundborg P (1990a) Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 39: 51–54
Andersson A, Lagerström PO, Unge P (1990b) A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 12: 329–333
Andersson T, Lundborg P, Regardh CG (1991) Lack of effect of omeprazole treatment on steady state plasma levels of metoprolol. Eur J Clin Pharmacol 40: 61–65
Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, Maurel P (1990) Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P-450. Gastroenterology 99: 737–747
Gugler R, Jensen JC (1985) Omeprazole inhibits oxidative drug metabolism; studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89: 1235–1241
Gugler R, Jensen JC (1987) Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 33: 133–137
Hendeles L, Iafrate RP, Weinberger M (1984) Clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. Clin Pharmacokinet 9: 95–135
Hendeless L, Massanari D, Weinberger M (1987) Theophylline. In: WE Evans, JJ Schentag, WJ Jusko (eds). Applied pharmacokinetics; principles of therapeutic drug monitoring. Spokane, WA — 2nd Edition, Chapter 32, pp 1105–1188
Henry D, Brent P, Whyte I, Mihaly G, Devenish-Meares S (1987) Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 33: 369–373
Houston JB (1982) Drug metabolites kinetics. Pharmac Ther 15: 521–552
Howden CW (1991) Clinical pharmacology of omeprazole. Clin Pharmacokinet 20: 38–49
Naline E, Flouvat B, Advenier C, Pays M (1987) Determination of theophylline and its metabolites in plasma and urine by reversed-phase liquid chromatography using an amine modifier. J Chromatogr 419: 177–189
Ogilvie RI (1978) Clinical pharmacokinetics of theophylline. Clin pharmacokinet 3: 267–293
Orcutt JJ, Kozak PP, Gillman SA, Cummins LH (1977) Micro-scale method for theophylline in body fluids by reverse phase high pressure liquid chromatography. Clin Chem 23: 599–601
Robson RA, Miners JO, Matthews AP, Stupans I, Meller D, McManus ME, Birkett DJ (1988) Characterisaton of theophylline metabolism by human liver microsomes. Biochem Pharmacol 37: 1651–1659
Rowland M, Tozer TN (1989) Clinical pharmacokinetics; concepts and applications 2nd ed. Lea and Febiger Philadelphia
Sarkar M, Polk RE, Guzelian PS, Junt C, Karnes HT (1990) In vitro effet of fluoroquinolones on theophylline metabolism in human liver microsomes. Ant Microb Agents Chemother 34: 594–599
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Taburet, A.M., Geneve, J., Bocquentin, M. et al. Theophylline steady state pharmacokinetics is not altered by omeprazole. Eur J Clin Pharmacol 42, 343–345 (1992). https://doi.org/10.1007/BF00266361
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00266361